entertainment -WSS

entertainment

author：focus 2025-10-02 01:07:45 - browse：84322

Mathai Mammen crosses his arms and looks into the camera — coverage from STAT — FogPharma CEO Mathai Mammen Boston Globe Photo Import

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing that few other biotechs have hit in recent years.

FogPharma, which is headquartered in Cambridge, Mass., is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells.

As CEO Mathai Mammen sees it, very few exemplary medicines shuttle off of drug companies’ pipelines, wade through clinical trials, and end up in the hands of physicians and patients in a given year. Far more often, pharma and biotech companies are pushing out drugs that are incrementally better than what came before, extending cancer patients’ survival by a few more months, halting their tumor growth for a little while longer. But FogPharma could deliver something truly unique, Mammen said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： What Kate Middleton's cancer revelation might teach the world

WSS

What the airline industry can learn from medicine

Steward Health Care expansion into Malta flopped

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Amazon expands telehealth clinic nationwide

Adam's Take: Intra

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

focus

entertainment

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mirador, a new biotech startup, launches with $400 million

Apple is now the first public company to be valued at $3 trillion

Pregnancy ages women, but effects reverse after delivery

Supreme Court strikes down use of affirmative action

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Duchenne breakthrough therapy leaves behind pioneering families

Asbestos ban is immediate, but health effects will linger for decades

Bright Health sells Medicare Advantage business to Molina

Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

National panel will explore requiring free Covid tests

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Adam's Take: Intra

Cancer, immunology, HIV research ensnared in fetal tissue politics

Micronoma's microbiome cancer diagnostic approach under fire

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

hotspot

focus

hotspot

Wikipedia